Introduction Approximately 50% of cancer patients will receive palliative radiotherapy (RT) during the course of their disease [ ]. Bone metastases (BMs) remain a significant concern in the radiation oncology setting, and 70% of BMs occur in the axial skeleton…
Introduction Bone metastasis is prevalent in the advanced stages of both breast and prostate cancer, and is a frequent finding in patients that succumb to these two diseases. Although breast cancer metastasizes to multiple body tissues, including bone, lung, liver,…
Research highlights Bone cancer pain is the most common presenting symptom in patients with skeletal metastases. Bone cancer pain has both nociceptive and neuropathic components. Persistent afferent stimulus from tumor-bearing bone induces peripheral and central sensitization. Bone cancer pain is…
Acknowledgments We would like to acknowledge the Nuclear Medicine Department and the Centre for PET at Austin Hospital, Melbourne, Australia, for providing the images; Dr. Alan Wong from the Austin Department of Pathology for assisting with photographing the histology slides.…
Research highlights Overview of image-guided biopsies using ultrasound, fluoroscopy, CT fluoroscopy, CT, and MRI Role of transarterial tumor embolization of hypervascular tumors as an adjuvant or radical therapy A review of thermal ablation techniques including radiofrequency ablation and cryoablation Controversies…
Introduction Bone is a site of both primary cancer as well as bone metastasis giving rise to secondary cancers. Primary bone cancers include osteosarcoma (OS), Ewing's sarcoma (ES), and multiple myeloma (MM). The major bone metastatic cancers include breast cancer…
Introduction The human skeleton is a multifunctional tissue responsible for a variety of functions including biomechanical support, protection of vital organs, strength, and mobility as well as the maintenances of calcium and phosphate homeostasis [ ]. Stephen Paget was the…
Research highlights Management of bone sarcomas in reference center improves compliance to guidelines and survival. Antiangiogenic tyrosine kinase inhibitors exert significant antitumor activity in most primary bone cancers. Second-line cytotoxic chemotherapy regimens have demonstrated activity in Ewing's sarcoma. Immunotherapy with…
Introduction Primary malignant tumors of the bone represent less than 1% of all cancer cases in the European population. The world age-standardized incidence rate is in the range of 0.5–2/100,000/year [ ]. In 2020, an estimated 3600 new cases and…
Introduction Close to 1% of all tumors are primary malignant bone tumors. Out of these, the chondrosarcoma is the second most common primary malignant bone tumor in adults with an incidence of 3–4/100,000 per year. Chondrosarcoma is the collective term…